Uterine cancer
Drug research and approvals for uterine cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 707 studies of uterine cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 3 drug trials for it since 2013.
- Recruiting worldwide: 707
- Trials authorized in Canada: 3
- FDA orphan approvals: 0
- EU medicines: 0
- Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) InjectionNCT07947043 · Phase 1 · Tongji Hospital · starts Apr 22, 2025
- Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine…NCT07942168 · Phase 2 · Blokhin's Russian Cancer Research Center · starts Jan 24, 2023
- Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA)NCT07938385 · Not reported · Royal Marsden NHS Foundation Trust · starts May 20, 2022
- Improving Rural Endometrial Cancer CareNCT07927244 · Not applicable · UNC Lineberger Comprehensive Cancer Center · starts May 9, 2025
- C2001P-CS6: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIVNCT07925307 · Not applicable · University of California, San Diego · starts Oct 16, 2026
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsNCT07909031 · Phase 1 / Phase 2 · Crescent Biopharma, Inc. · starts Oct 21, 2026
- Hydrogel Spacer During Definitive Radiotherapy for Cervical CancerNCT07904182 · Not applicable · Tianjin Medical University Cancer Institute and Hospital · starts Oct 12, 2026
- Benefits of cinEmA Sessions During Radio-chemoTherapy on Outcomes of Patients With ceRvIcal canCErNCT07902180 · Not applicable · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · starts Jun 1, 2026
- Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological CancersNCT07902375 · Not applicable · Universiteit Antwerpen · starts Jun 19, 2026
Approved 5
- BevacizumabUterine cervical cancer · Vascular endothelial growth factor A inhibitor
- PembrolizumabEndometrial cancer · Programmed cell death protein 1 inhibitor
- TopotecanUterine cervical cancer · DNA topoisomerase I inhibitor
- DostarlimabEndometrial cancer · Programmed cell death protein 1 antagonist
- Tisotumab vedotinUterine cervical cancer · Tubulin inhibitor
Phase 3 12 of 60
- CisplatinUterine cervical cancer · DNA inhibitor
- PaclitaxelUterine cervical cancer · Tubulin inhibitor
- CarboplatinUterine cervical cancer · DNA inhibitor
- DoxorubicinEndometrial cancer · DNA topoisomerase II alpha inhibitor
- LetrozoleEndometrial cancer · Cytochrome P450 19A1 inhibitor
- GemcitabineUterine cervical cancer · Ribonucleoside-diphosphate reductase RR1 inhibitor
- CadonilimabUterine cervical cancer · Programmed cell death protein 1 inhibitor
- DocetaxelUterine cervical cancer · Tubulin inhibitor
- Medroxyprogesterone acetateEndometrial cancer · Progesterone receptor agonist
- MetforminEndometrial cancer · Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NimotuzumabUterine cervical cancer · Epidermal growth factor receptor erbB1 inhibitor
- ZimberelimabUterine cervical cancer · Programmed cell death protein 1 inhibitor
Phase 2 12 of 140
- CamrelizumabUterine cervical cancer · Programmed cell death protein 1 antagonist
- EverolimusEndometrial cancer · FK506-binding protein 1A inhibitor
- ToripalimabUterine cervical cancer · Programmed cell death protein 1 antagonist
- TislelizumabUterine cervical cancer · Programmed cell death protein 1 inhibitor
- NiraparibEndometrial cancer · Poly [ADP-ribose] polymerase 2 inhibitor
- SintilimabUterine cervical cancer · Programmed cell death protein 1 antagonist
- CapecitabineUterine cervical cancer · Thymidylate synthase inhibitor
- CetuximabUterine cervical cancer · Epidermal growth factor receptor erbB1 inhibitor
- Mirvetuximab soravtansineEndometrial cancer · Folate receptor alpha binding agent
- AmifostineUterine cervical cancer · Reactive metabolite scavenging agent
- NivolumabUterine cervical cancer · Programmed cell death protein 1 inhibitor
- BuparlisibEndometrial cancer · PI3-kinase class I inhibitor
Phase 1 or earlier 12 of 49
- CidofovirUterine cervical cancer · Human herpesvirus 1 DNA polymerase inhibitor
- NelfinavirUterine cervical cancer · Human immunodeficiency virus type 1 protease inhibitor
- SS1(DSFV)-PE38Uterine cervical cancer · Mesothelin binding agent
- Denileukin diftitoxEndometrioid cancer · Elongation factor 2 inhibitor
- FludarabineUterine cervical cancer
- AldesleukinUterine cervical cancer · Interleukin-2 receptor agonist
- Trastuzumab emtansineEndometrial cancer · Receptor protein-tyrosine kinase erbB-2 binding agent
- BosutinibUterine cervical cancer · Tyrosine-protein kinase ABL inhibitor
- ImatinibTyrosine-protein kinase ABL inhibitor
- SorafenibUterine cervical cancer · Serine/threonine-protein kinase RAF inhibitor
- AnastrozoleEndometrial cancer · Cytochrome P450 19A1 inhibitor
- MiransertibEndometrial cancer · Serine/threonine-protein kinase AKT inhibitor
How its trials ended
228 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 49 whose ending is known, 29% met their primary endpoint, 8% missed it and 63% stopped early.
- Completed, result not reported8738%
- Ongoing6629%
- Status unknown2611%
- Stopped: other or unclear157%
- Met its primary endpoint146%
- Stopped: enrollment or feasibility125%
- Missed its primary endpoint42%
- Stopped: sponsor or business decision31%
- Stopped: safety1<1%
| May 30, 2024 | Beamion pantumor-1: a phase II, multicentre, multicohort, open label trial to evaluate the efficacy and safety of oral zongertinib (bi 1810631) for the…Zongertinib (bi 1810631) | Boehringer Ingelheim (Canada) Ltd Ltee | Ongoing |
| Nov 21, 2023 | Phase I study of the PKMYT1 inhibitor RP-6306 in combination with carboplatin and paclitaxel for the treatment of recurrent TP53 ovarian and uterine cancer…Lunresertib (RP-6306) | University Health Network | Closed |
| Aug 25, 2023 | The epoch study: phase II open labelled study investigating the use of single agent eribulin and eribulin in combination with pembrolizumab in relapsed…Eribulin/ Pembrolizumab | Dr. Amit Oza | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA